Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2005 | 09-2005 | 06-2005 | 03-2005 | 12-2004 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 19,132 | 6,636 | 10,060 | 13,130 | 16,008 |
| Receivables | 414 | 41 | 68 | N/A | N/A |
| Inventories | 279 | 45 | 31 | 47 | 52 |
| TOTAL | $20,106 | $6,937 | $10,546 | $13,540 | $16,146 |
| Non-Current Assets | |||||
| PPE Net | 381 | 425 | 371 | 316 | 236 |
| Other Non-Current Assets | 23 | 23 | 21 | 20 | 23 |
| TOTAL | $404 | $448 | $392 | $336 | $258 |
| Total Assets | $20,510 | $7,385 | $10,938 | $13,877 | $16,404 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,380 | 1,441 | 1,414 | 1,769 | 1,487 |
| Accrued Expenses | 669 | 370 | 302 | 159 | 92 |
| TOTAL | $2,303 | $1,812 | $1,715 | $1,928 | $1,579 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 254 | N/A | N/A | N/A | N/A |
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,303 | $1,812 | $1,715 | $1,928 | $1,579 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 60,301 | 50,046 | 49,962 | 49,922 | 49,502 |
| Common Shares | 60 | 50 | 50 | 50 | 49 |
| Retained earnings | -26,347 | -22,834 | -19,133 | -16,265 | -13,072 |
| TOTAL | $18,207 | $5,574 | $9,223 | $11,949 | $14,824 |
| Total Liabilities And Equity | $20,510 | $7,385 | $10,938 | $13,877 | $16,404 |